Related Experiment Video
Updated: Aug 15, 2026

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
Published on: August 17, 2022
Tako-Tsubo cardiomyopathy: new insights into the possible underlying pathophysiology
Elisa Merli1, Stephen Sutcliffe, Mauro Gori
1St George's Hospital, Department of Cardiology, Blackshaw Road, London SW 17-0Q8, UK. elisamerli@libero.it
Insights
Tako-Tsubo cardiomyopathy may stem from abnormal heart structure and stress. Localized septal thickening causes transient obstruction, leading to ischemia and stunning, particularly in women.
Area of Science:
- Cardiology
- Cardiovascular Pathophysiology
- Cardiac Imaging
Background:
- Tako-Tsubo cardiomyopathy (TTC) presents with atypical left ventricular (LV) dysfunction and normal coronary angiography.
- Pathophysiology remains unclear, with theories including catecholamine surge, epicardial, or microvascular spasm.
Observation:
- A series of four female patients with TTC exhibited transient LV mid-apical dyskinesis and dynamic mid-cavity obstruction.
- This obstruction was linked to localized mid-ventricular septal thickening.
- Stress echocardiography revealed LV mid-cavity gradients and myocardial stunning.
Findings:
- Abnormal myocardial architecture, specifically localized mid-ventricular septal thickening, is a key factor in TTC.
- This thickening, combined with stress (physical/emotional) and dehydration, causes transient LV mid-cavity obstruction.
- The obstruction creates high-pressure apical chambers, inducing sub-endocardial ischemia and stunning.
Implications:
- This mechanism explains TTC's ischemia unrelated to specific coronary territories.
- Rehydration and reduced catecholamines resolve the obstruction and improve function.
- Strain/strain rate dobutamine stress echocardiography confirms myocardial stunning as the substrate.
Unlabelled:
Tako-Tsubo cardiomyopathy is characterised by an atypical distribution of left ventricular (LV) dysynergy with apical ballooning and compensatory basal hyperkinesis. Coronary angiography is normal. Several substrates have been put forward to explain the underlying pathophysiology such as raised catecholamine levels (due to physical or emotional stress), multivessel epicardial coronary spasm or diffuse microvascular spasm. However, the pathophysiology has not yet been fully clarified. We present a series of cases whose findings could explain the mechanism underlying this syndrome. Four consecutives patients, all female, were admitted with the clinical features typical of Tako-Tsubo syndrome. In all, severe widespread transient LV mid-apical a/dyskinesia was associated with a mid-cavity dynamic obstruction which resolved prior to the resolution of the LV wall motion abnormalities. In all cases the dynamic LV obstruction was related to localised mid-ventricular septal thickening. After improvement in wall motion, a low-dose strain/strain rate dobutamine stress-echocardiography (DSE) was performed to determine the underlying ischaemic substrate. This provoked an LV mid-cavity gradient at peak dose in all. Regional deformation changes during DSE showed the affected myocardium to have the typical response diagnostic of regional stunning.
Conclusion:
We postulate that an important unrecognised factor in the development of Tako-Tsubo cardiomyopathy is the presence of abnormal myocardial functional architecture (such as localised mid-ventricular septal thickening), which in the presence of dehydration and/or raised catecholamine levels due to physical or emotional stress, leads the development of a severe transient LV mid-cavity obstruction. This effectively sub-divides the LV into two functionally different chambers with a marked increase in wall stress in the high pressure distal apical chamber. This, in combination with the abnormal high circulating catecholamine levels, induces widespread sub-endocardial ischaemia which is unrelated to a specific coronary artery territory. With rehydration/fall in catecholamine levels the interventricular gradient resolves and distal function recovers. Low dose SR/S DSE confirms that the distal ischaemic substrate is myocardial stunning.
Related Concept Videos
Coronary Artery Disease II: Pathophysiology
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Myocarditis I: Introduction